BioXcel Therapeutics is trading 6.39% down now at $0.17 in after-hours trading after its August 27, 2026 Chapter 11 filing and proposed court-supervised asset sale to Teva Pharmaceuticals.
- Teva would pay $57.5 million upfront, with up to $67.5 million in contingent milestone payments.
- Reuters reported estimated liabilities of $100 million-$500 million versus assets of $10 million-$50 million, intensifying uncertainty for shareholders.
- The regular session closed 74.76% lower at $0.18 on August 28, 2026.